SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla planning to enter branded formulation market in China: Report

09 Nov 2017 Evaluate

Cipla is reportedly planning to enter the branded formulation market in China in coming quarters either by acquiring a company or collaborating with a local partner. The company is planning to focus on respiratory therapeutics in the country.

Cipla’s proposed entry into China’s branded respiratory segment is in line with its pursuit to build a global respiratory franchise. The segment alone contributed about one-fifth to Cipla’s sales of Rs 14,630 crore in FY17.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1452.35 -18.90 (-1.28%)
07-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1903.00
Dr. Reddys Labs. 1353.75
Cipla 1452.35
Zydus Lifesciences 1152.90
Lupin 2489.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: